A method for removing characteristic genotoxic impurities in deflazacort raw material

By stirring and dissolving difcote with acetic acid and add water dropwise at 50-55°C, the genotoxic impurities in difcote are removed by using a mixed solution of methanol, acetone and a cosolvent, and the genes in the prior art are solved. The problem of toxic impurities residues improves the purity and safety of the drug and meets strict regulatory requirements.

CN117586335BActive Publication Date: 2024-11-05HUNAN STEROIDCHEM PHARM CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202311592460.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-27
Publication Date
2024-11-05
Estimated Expiration
2043-11-27

AI Technical Summary

Technical Problem

In the prior art, the residual genotoxic impurities in the difcote drug are difficult to effectively remove, which affects the safety of the drug and the time of marketing of the new drug. In addition, the existing refining schemes have high residues of genotoxic impurities.

Method used

By stirring and dissolving difcote and acetic acid at 50-55°C, then adding water dropwise and cooling, the genotoxic impurities are removed by using a mixed solution of methanol, acetone and co-solvent. Acetic acid inhibits the generation of impurities and gradually precipitates difcote Specially, thereby removing impurities.

Benefits of technology

It significantly reduces the content of genotoxic impurities in difcote, improves the purity and safety of the drug, meets strict regulatory requirements, and shortens the time for new drugs to go to market.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117586335B_ABST
    Figure CN117586335B_ABST
Patent Text Reader

Abstract

The invention discloses a method for removing characteristic genotoxic impurities in a deflazacort raw material drug, and belongs to the technical field of drug synthesis. The method for removing characteristic genotoxic impurities in a deflazacort raw material drug comprises the following steps: adding a crude deflazacort product and acetic acid to a mixed solution, stirring and dissolving at 50 to 55° C., then dripping water, and then cooling to obtain purified deflazacort; the mixed solution is obtained by mixing methanol, acetone and a cosolvent. The removal method can effectively remove residual genotoxic impurities in deflazacort.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug synthesis, and in particular to a method for removing characteristic genotoxic impurities in a deflazacort raw material drug. Background Art

[0002] Deflazacort is a third-generation glucocorticoid and an important drug for the treatment of primary adrenocortical insufficiency, skin diseases, rheumatism, fulminant and disseminated pulmonary tuberculosis and other diseases. The annual demand at home and abroad reaches 200 tons. Its anti-inflammatory effect is much higher than prednisolone, hydrocortisone, etc. After its successful development in the 1980s, it has been widely used in the treatment of inflammatory and immune diseases. Recently, the US FDA officially approved it as a remission hormone drug for DMD (Duchenne muscular dystrophy), and it has achieved significant results. The CAS number of deflazacort is: 14484-47-0, and the molecular formula is: C 25 H 31 NO6, molecular weight: 383.48, its structural formula is as follows:

[0003]

[0004] The finished product of Deflazacort obtained by the existing synthesis method (as shown in the figure below) contains a certain amount of genotoxic impurities. Genotoxic impurities refer to substances that can cause DNA mutations, chromosome breaks or DNA recombination. Such substances may also cause the occurrence of human tumors.

[0005]

[0006] Genotoxic impurities mainly come from starting materials, intermediates, reagents and reaction by-products in the synthesis process of APIs. In addition, drugs may also degrade and produce genotoxic impurities during synthesis, storage or preparation. In recent years, with the gradual improvement of genotoxic impurity regulations, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and other departments have increasingly stringent regulatory requirements for genotoxic impurities. If genotoxic impurities in drugs are not properly controlled, they may lead to clinical risks and also affect the time it takes for new drugs to be marketed. The removal of genotoxic impurities is crucial.

[0007] The content of genotoxic impurities in the registration application process of deflazacort API needs to be strictly controlled. The existing refining scheme will have considerable genotoxic impurities remaining, increasing the risk of using deflazacort API. There is an urgent need in this field for a method to remove this specific genotoxic impurity, so as to effectively remove the genotoxic impurity remaining in the current deflazacort chemical synthesis process, provide high-purity deflazacort, and increase the safety of the drug.

[0008] The structural formula of the genotoxic impurity of Deflazacort is as follows:

[0009] Summary of the invention

[0010] The purpose of the present invention is to overcome the above technical deficiencies, provide a method for removing characteristic genotoxic impurities in deflazacort raw materials, and solve the technical problem of how to effectively remove residual genotoxic impurities in deflazacort in the prior art.

[0011] In order to achieve the above technical objectives, the technical solution of the present invention provides a method for removing characteristic genotoxic impurities in deflazacort raw materials, comprising the following steps:

[0012] Deflazacort and acetic acid are added to the mixed solution, stirred at 50-55° C. to dissolve, then water is added dropwise, and then the temperature is lowered to obtain purified deflazacort; the mixed solution is obtained by mixing methanol, acetone and a co-solvent.

[0013] In some embodiments, in the mixed liquid, the mass ratio of the methanol to the acetone is 2:(1-1.5).

[0014] In some embodiments, in the mixed liquid, the mass ratio of the methanol to the co-solvent is 1:(1-1.5).

[0015] In some embodiments, the mass ratio of deflazacort to water is 1:(5-6).

[0016] In some embodiments, the time required to complete the dropwise addition of water is 0.5-1 h.

[0017] In some embodiments, the mass ratio of the deflazacort to the acetic acid is 1:(0.1-0.2).

[0018] In some embodiments, the co-solvent is dichloromethane.

[0019] In some embodiments, the temperature is lowered to 0-5°C to obtain the purified deflazacort.

[0020] In some embodiments, the method further comprises adding purified deflazacort and acetic acid to the mixture for further purification.

[0021] Compared with the prior art, the beneficial effects of the present invention include: in the mixed solution, deflazacort is dissolved under the joint action of methanol, acetone and a co-solvent, acetic acid can inhibit the generation of genotoxic impurities, first stirring and dissolving at 50-55° C., and then dripping water can reduce the solubility so that deflazacort is slowly precipitated, and the impurities remain in the solvent, thereby achieving effective removal of residual genotoxic impurities in deflazacort. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the carbon spectrum of the purified deflazacort according to Example 1 of the present invention.

[0023] Figure 2 This is the hydrogen spectrum of the purified deflazacort according to Example 1 of the present invention. DETAILED DESCRIPTION

[0024] In the following description, references to “some embodiments,” “this embodiment,” “this embodiment,” and examples, etc., describe a subset of all possible embodiments, but it can be understood that “some embodiments” may be the same subset or different subsets of all possible embodiments, and may be combined with each other without conflict.

[0025] If similar descriptions of "first / second" appear in the application documents, the following instructions are added. In the following description, the terms "first\second\third" involved are merely used to distinguish similar objects and do not represent a specific ordering of the objects. It can be understood that "first\second\third" can be interchanged in a specific order or sequence where permitted, so that the present embodiment described here can be implemented in an order other than that illustrated or described here.

[0026] In this embodiment, the term "and / or" is merely a description of the association relationship between associated objects, indicating that three relationships may exist. For example, object A and / or object B may represent three situations: object A exists alone, object A and object B exist at the same time, and object B exists alone.

[0027] This specific embodiment provides a method for removing characteristic genotoxic impurities in deflazacort raw materials, comprising the following steps:

[0028] Add crude deflazacort and acetic acid to the mixed solution, stir and dissolve at 50-55°C, then add water dropwise for 0.5-1h to complete the addition of water, and then cool to 0-5°C to obtain purified deflazacort; the mixed solution is obtained by mixing methanol, acetone and a co-solvent; the mass ratio of the methanol to the acetone is 2:(1-1.5); the mass ratio of the methanol to the co-solvent is 1:(1-1.5); the mass ratio of the crude deflazacort to the water is 1:(5-6); the mass ratio of the crude deflazacort to the acetic acid is 1:(0.1-0.2); the co-solvent is dichloromethane.

[0029] In order to further purify deflazacort, in some embodiments, the purified deflazacort and acetic acid are further added to the mixture for further purification.

[0030] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0031] Example 1

[0032] This embodiment provides a method for removing characteristic genotoxic impurities in deflazacort API, comprising the following steps:

[0033] 1 g of deflazacort and 0.1 g of acetic acid were added to the mixed solution, stirred at 50-55°C to dissolve, then 5 g of water was added dropwise, and the addition of water was completed after 0.5 h, and then the temperature was lowered to 0-5°C to obtain a purified deflazacort filter cake, which was then filtered, washed with a small amount of water, drained, discharged, and dried; the mixed solution was obtained by mixing 2 g of methanol, 1 g of acetone, and 2 g of dichloromethane. In this embodiment, the yield of deflazacort was 98.8%, and the content of genotoxic impurities decreased from 379.07 ppm to 30.24 ppm.

[0034] Figure 1 and Figure 2 These are the carbon spectrum and hydrogen spectrum of purified deflazacort, respectively.

[0035] Example 2

[0036] This embodiment provides a method for removing characteristic genotoxic impurities in deflazacort API, comprising the following steps:

[0037] 1 g of crude deflazacort and 0.1 g of acetic acid were added to the mixed solution, stirred at 50-55°C to dissolve, and then 6 g of water was added dropwise. The addition of water was completed after 1 hour, and then the temperature was lowered to 0-5°C to obtain a purified deflazacort filter cake, which was then filtered, washed with a small amount of water, drained, discharged, and dried; the mixed solution was obtained by mixing 2 g of methanol, 1.5 g of acetone and 3 g of dichloromethane.

[0038] In this example, the yield of deflazacort was 98.3%, and the content of genotoxic impurities decreased from 379.07 ppm to 33.38 ppm.

[0039] Example 3

[0040] This embodiment provides a method for removing characteristic genotoxic impurities in deflazacort API, comprising the following steps:

[0041] 1 g of crude deflazacort and 0.2 g of acetic acid were added to the mixed solution, stirred at 50-55°C to dissolve, then 5.5 g of water was added dropwise, and the addition of water was completed after 1 hour. Then the temperature was lowered to 0-5°C to obtain a purified deflazacort filter cake, which was then filtered, washed with a small amount of water, drained, discharged, and dried; the mixed solution was obtained by mixing 2 g of methanol, 1.2 g of acetone and 2.5 g of dichloromethane.

[0042] In this example, the yield of deflazacort was 97.9%, and the content of genotoxic impurities decreased from 379.07 ppm to 35.43 ppm.

[0043] Example 4

[0044] This embodiment also proposes a method for removing characteristic genotoxic impurities in the deflazacort raw material, comprising the following steps:

[0045] The filter cake obtained in Example 1 was purified again according to the removal method and dosage ratio of each substance in Example 1.

[0046] In this example, the yield of deflazacort was 88.9%, and the content of genotoxic impurities decreased from 30.24 ppm to 6.04 ppm.

[0047] Example 5

[0048] This embodiment also proposes a method for removing characteristic genotoxic impurities in the deflazacort raw material, comprising the following steps:

[0049] The filter cake obtained in Example 2 was purified again according to the removal method and dosage ratio of each substance in Example 2.

[0050] In this example, the yield of deflazacort was 88.9%, and the content of genotoxic impurities decreased from 33.38 ppm to 7.28 ppm.

[0051] Example 6

[0052] This embodiment also proposes a method for removing characteristic genotoxic impurities in the deflazacort raw material, comprising the following steps:

[0053] The filter cake obtained in Example 3 was purified again according to the removal method and dosage ratio of each substance in Example 3.

[0054] In this example, the yield of deflazacort was 88.9%, and the content of genotoxic impurities decreased from 35.43 ppm to 8.17 ppm.

[0055] Comparative Example 1

[0056] This comparative example proposes a method for removing characteristic genotoxic impurities in deflazacort raw materials, comprising the following steps:

[0057] 1 g of crude deflazacort and 0.1 g of acetic acid were added to the mixture, stirred at 50-55°C to dissolve, then cooled to 0-5°C to obtain purified deflazacort, then filtered, washed with a small amount of water, dried, and discharged; the mixture was composed of 2 g of methanol, 1.2 g of acetone, and 2.5 g

[0058] Dichloromethane was mixed.

[0059] In this comparative example, the yield of deflazacort was 71.3%, and the content of genotoxic impurities changed from 379.07 ppm to 302.61 ppm.

[0060] Comparative Example 2

[0061] This comparative example proposes a method for removing characteristic genotoxic impurities in deflazacort raw materials, comprising the following steps:

[0062] 1 g of crude deflazacort was added to the mixed solution, stirred at 50-55°C to dissolve, then 5 g of water was added dropwise, and the addition of water was completed after 0.5 h. Then the temperature was lowered to 0-5°C to obtain purified deflazacort, which was then filtered, washed with a small amount of water, dried, and discharged; the mixed solution was obtained by mixing 2 g of methanol, 1.2 g of acetone, and 2.5 g of dichloromethane.

[0063] In this comparative example, the yield of deflazacort was 97.2%, and the content of genotoxic impurities changed from 379.07 ppm to 252.61 ppm.

[0064] Comparative Example 3

[0065] This comparative example proposes a method for removing characteristic genotoxic impurities in deflazacort raw materials, comprising the following steps:

[0066] 1 g of crude deflazacort and 0.1 g of acetic acid were added to the mixed solution, stirred at 50-55°C to dissolve, and then water was added dropwise for 0.5-1 h to complete the addition of water, and then the temperature was lowered to 0-5°C to obtain purified deflazacort, which was then filtered, washed with a small amount of water, drained, and discharged; the mixed solution was obtained by mixing 2 g of methanol and 3.7 g of dichloromethane.

[0067] In this comparative example, the yield of deflazacort was 85.3%, and the content of genotoxic impurities decreased from 379.07 ppm to 251.52 ppm.

[0068] The specific implementation of the present invention described above does not constitute a limitation on the protection scope of the present invention. Any other corresponding changes and modifications made based on the technical concept of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A method for removing characteristic genotoxic impurities in deflazacort raw materials, characterized in that: The following steps are involved: Deflazacort and acetic acid are added to a mixed solution, stirred at 50-55°C to dissolve, then water is added dropwise, and then the temperature is lowered to obtain purified deflazacort; the mixed solution is obtained by mixing methanol, acetone and a co-solvent; in the mixed solution, the mass ratio of the methanol to the acetone is 2:(1-1.5); the mass ratio of the methanol to the co-solvent is 1:(1-1.5); the mass ratio of the deflazacort to the water is 1:(5-6); the mass ratio of the deflazacort to the acetic acid is 1:(0.1-0.2); the co-solvent is dichloromethane.

2. The method for removing characteristic genotoxic impurities in the deflazacort raw material according to claim 1, characterized in that: The time required to complete the dropwise addition of water is 0.5-1 h.

3. The method for removing characteristic genotoxic impurities in the deflazacort bulk drug according to claim 1, characterized in that: The temperature was lowered to 0-5°C to obtain the purified deflazacort.

4. The method for removing characteristic genotoxic impurities in the deflazacort bulk drug according to claim 1, characterized in that: The method also includes adding the purified deflazacort and acetic acid to the mixed solution for re-purification.

Citation Information

Cited By

  • Method for targeted removal of genotoxic impurities in the synthesis of heterocyclic drug substances

    CN123026485A